A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Wadonda Kabondo, Nellie ^a,b   Hedt, Bethany L ^b   Van Oosterhout, Joep J ^c   Moyo, Kundai ^a   Limbambala, Eddie ^d   Bello, George ^a   Chilima, Ben ^a   Schouten, Erik ^a   Harries, Anthony ^e,f   Massaquoi, Moses ^g,h   Porter, Carol ⁱ   Weigel, Ralf ^j,k   Hosseinipour, Mina ^l   Aberle Grasse, John ^m   Jordan, Michael R ^d,n   Kabuluzi, Storn ^a   Bennett, Diane E ^m  

^a MINISTRY OF HEALTH   (Malawi)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MALAWI   (Malawi)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g MÉDECINS SANS FRONTIÈRES   (Belgium)

^h Thyolo District Hospital   (Malawi)

ⁱ HOWARD UNIVERSITY   (United States)

^j LIGHTHOUSE TRUST   (Malawi)

^k LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^l UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^m CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁿ TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SURVEILLANCE; FEMALE; HEALTH CENTER; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALAWI; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PREVENTION STUDY; PRIORITY JOURNAL; PUBLIC HEALTH; RETROSPECTIVE STUDY; REVIEW; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALAWI; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 84860354396     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis004     Document Type: Review

References (25)

1. Ministry of Health. Treatment of AIDS: guidelines for the use of antiviral therapy in Malawi. Lilongwe, Malawi: Ministry of Health, 2006.
2. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-95. (Pubitemid 38553709)
3. Barth RE, van der Loeff MF, Schaorman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155-66.
4. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of longterm viral failure among Ugandan children and adults treated with antiretroviral therapy. JAIDS 2007; 46:187-93. (Pubitemid 47482614)
5. Marcelin AG, Jarrousse B, Derache A, et al. HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen. AIDS 2007; 21:2341-3. (Pubitemid 350287461)
6. Maldonado F, Biot M, Roman F, et al. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique. Trans R Soc Trop Med Hyg 2008 doi: 10. 1016/j. trstmh. 2008. 07. 014.
7. Koyalta D, Charpentier C, Beassamda J, et al. High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clin Infect Dis 2009; 49:155-9.
8. Kouanfack C, Montavon C, Laurent C, et al. Low levels of antiretroviralresistant HIV infection at a routine clinic in Cameroon that uses the-World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment. Clin Infect Dis 2009; 48:1318-22.
9. Hosseinipour MC, van Oosterhout JJG, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-34.
10. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:480-4.
11. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-97. (Pubitemid 351706742)
12. Puthanakit T, Jourdain G, Hongsiriwon P, et al. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transciptase inhibitor-based antiretroviral therapy. HIV Med 2010 doi: 10. 1111/j. 1468-1293. 2010. 00828. x.
13. Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Saekang N, Pairoj W, ChantratitaW. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine and nevirapine. J Clin Virol 2008; 41:310-3.
14. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-71. (Pubitemid 46684328)
15. Johannessen A, Naman E, Kivuyo SL, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 2009; 9:108.
16. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13(Suppl 2):1-13. (Pubitemid 352019085)
17. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for the surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13(Suppl 2):25-36. (Pubitemid 352019087)
18. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13(Suppl 2):15-23. (Pubitemid 352019086)
19. World Health Organization. HIV drug resistance early warning indicators: World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites. Available at: www.who.int/hiv/topics/ drugresistance/hiv-dr-early-warning-indicators.pdf.Accessed 15 July 2011.
20. Kamoto K, Aberle-Grasse J; on behalf of Members of the Malawi HIV Drug Resistance Task Force. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi. Antivir Ther 2008; 13(Suppl 2):83-7. (Pubitemid 352019093)
21. Hedt BL, Wadonda-Kabondo N, Makombe S, et al. Early warning indicators for HIV drug resistance in Malawi. Antivir Ther 2008; 13(Suppl 2):69-75. (Pubitemid 352019091)
22. Pillay V, Ledwaba J, Hunt G, et al. Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004. Antivir Ther 2008; 13(Suppl 2): 101-7. (Pubitemid 352019096)
23. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-18. Epub 2006 April 28. Available at: http://hivdb. stanford. edu/. Accessed 14 December 2011.
24. Yu JKL, Chen SCC, Wang KY, et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 2007; 85:552-4.
25. Nzeyimana SD, Baramperanye E, Mouacha F, et al. Monitoring of HIV-1 drug resistance and associated programmatic factors in patients initiating antiretroviral therapy at two ART sites in Bujumbura, Burundi. Antivir Ther 2010; 15(Suppl 2):A153.